SCHEMBL4833867

SCHEMBL4833867

NC1c2ccoc2N=CN1c1ccc(NC(=O)Nc2cccc(F)c2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MTOR P42345 1/20 0.43
▸ RAB9A P51151 9/20 0.42
▸ NPC1 O15118 7/20 0.42
▸ KMT2A Q03164 5/20 0.42
▸ MEN1 O00255 4/20 0.42
▸ MAPT P10636 2/20 0.42
▸ DDX3X O00571 5/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ POLB P06746 1/20 0.41
▸ CDK8 P49336 2/20 0.41
▸ KDR P35968 3/20 0.41
▸ LCK P06239 2/20 0.41
▸ LYN P07948 2/20 0.41
▸ PIM1 P11309 2/20 0.41
▸ FLT3 P36888 2/20 0.41
▸ BLK P51451 2/20 0.41
▸ RPS6KA3 P51812 2/20 0.41
▸ STK3 Q13188 2/20 0.41
▸ ROCK1 Q13464 2/20 0.41
▸ NTRK2 Q16620 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4833686 0.88 MEN1 (0.47) RAB9ANPC1KMT2AMEN1MAPT
SCHEMBL4833483 0.88 KMT2A (0.48) RAB9AKMT2AMEN1MAPTSMN1; SMN2
SCHEMBL4832995 0.87 NPC1 (0.46) RAB9ANPC1KMT2AMEN1MAPT
SCHEMBL4831187 0.86 MAPT (0.40) RAB9ANPC1KMT2AMEN1MAPT
SCHEMBL4828990 0.86 TP53 (0.50) RAB9ANPC1KMT2AMEN1MAPT
SCHEMBL4833638 0.86 MAPT (0.44) RAB9ANPC1KMT2AMEN1MAPT
SCHEMBL4834151 0.86 MAPT (0.50) RAB9ANPC1KMT2AMEN1MAPT
SCHEMBL4834445 0.85 TRPV1 (0.42) RAB9ANPC1KMT2AMEN1MAPT
SCHEMBL4833543 0.85 RIPK1 (0.44) MTORKDRAURKBAURKAFLT1
SCHEMBL4836210 0.85 CA12 (0.47) RAB9ANPC1KMT2AMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF ADAMS JERRY LEROY 2008-11-20 — — US claimed
US-20050004142-A1 Chemical compounds SMITHKLINE BEECHAM CORPORATION 2005-01-06 — — US claimed
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF ADAMS JERRY LEROY 2008-11-20 — — US disclosed
US-7427623-B2 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof SMITHKLINE BEECHAM CORPORATION (US) 2008-09-23 — — US disclosed
US-20050004142-A1 Chemical compounds SMITHKLINE BEECHAM CORPORATION 2005-01-06 — — US disclosed
EP-1425284-A2 FURO- AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-06-09 — — EP disclosed
WO-2003022852-A2 FURO-AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004142-A1 Chemical compounds TIE1, KDR, TEK MTOR 1009/4885RAB9A 3248/4885NPC1 4117/4885
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF TIE1, TEK, KDR MTOR 1029/4885RAB9A 4166/4885NPC1 4782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback